Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anokion Announces FDA Clearance of IND Application for its Lead Program in Celiac Disease
Details : Anokion plans to initiate its multi-center Phase 1 study for KAN-101 in people with celiac disease in the first quarter of 2020.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2020
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable